Henry Schein's stock soared 6.17% during intraday trading on Tuesday, driven by the company's better-than-expected fourth-quarter 2025 financial results and optimistic outlook for 2026.

The healthcare solutions provider reported adjusted earnings per share of $1.34 for Q4 2025, surpassing analyst estimates of $1.30. Revenue rose 7.7% to $3.44 billion, also beating expectations of $3.35 billion. The strong performance was attributed to robust growth in global equipment sales, particularly in the U.S., Germany, Brazil, Canada, and Australia, as well as significant gains in specialty products like dental implants and endodontics.

For 2026, Henry Schein forecast adjusted EPS of $5.23 to $5.37, with the midpoint above the consensus estimate of $5.29, and expects total sales growth of 3% to 5%. Additional positive factors included the appointment of a new CEO with extensive experience from Thermo Fisher and a $200 million share repurchase executed in the fourth quarter, further boosting investor sentiment.